Q32 Bio Inc (QTTB) News & EventsQTTBQ32 Bio Inc

Q32 Bio Inc Trading Halted Due to Volatility

Q32 Bio Inc trading halted, volatility trading pause

Q32 Bio Announces New Results from SIGNAL-AA Phase 2a Clinical Trial

Q32 Bio announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. These results were presented across a late-breaking oral and poster presentation at the European Academy of Dermatology and Venereology, or EADV, Congress 2026. Q32 Bio previously announced topline results from this trial in July 2026. Bempikibart is a fully human anti-IL-7Ralpha antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling. The Part B portion of the SIGNAL-AA program is an open-label clinical trial building upon the previously completed Part A, which established proof-of-concept of bempikibart in AA. In Part B, bempikibart is being evaluated in 33 patients with severe or very severe AA with a maximum duration of current episode of four years. Enrollment amongst patients with prior exposure to JAK inhibitor therapy was allowed; amongst the 33 enrolled patients, 36.4% had previously been treated with oral JAKis. Total enrollment exceeded the initial target due to patient demand. In Part B, patients are treated with bempikibart for 36 weeks, with 16-week off-drug follow-up through Week 52 before optional enrollment in the open-label extension. Dosing includes an initial loading regimen of 200mg of bempikibart dosed weekly for four doses, followed by continued dosing of 200mg every-other-week over a 32-week period, for a total dosing period of 36 weeks. Across both regimens, bempikibart was administered subcutaneously. The prespecified primary efficacy analysis was evaluated on the basis of mean percentage change from baseline in SALT scores in the modified intent-to-treat population. Additional prespecified efficacy analyses included the proportion of patients achieving various relative and absolute SALT improvements including SALT-20, SALT30, and SALT50 responses at Week 36. Patients were then followed through the off-drug period to Week 52. Bempikibart demonstrated clinically meaningful efficacy data on primary and key secondary endpoints at Week 36 supporting its advancement into a registration-directed program. Mean percent reduction in SALT score from baseline of 35.3% in the mITT analysis. 40.0% of patients in the mITT analysis and 30.3% of patients in the intent-to-treat analysis achieved a SALT-20 response. In addition to SALT-20 response being observed in patients with both severe and very severe disease, it was also observed in both IgE-high and IgE-low patients and in both patients with greater than and less than two-year duration of episode. 44.0% of patients in the mITT analysis and 33.3% of patients in the ITT analysis achieved SALT30 response. 44.0% of patients in the mITT and 33.3% of patients in the ITT analysis achieved SALT50 response.

Q32 Bio Files to Sell 6.88M Shares of Common Stock

Q32 Bio files to sell 6.88M shares of common stock for holders